Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Experts Recommend Approval of Sinovac’s H1N1 Flu Vaccine

publication date: Aug 31, 2009

Sinovac Biotech (北京科兴生物制品有限公司) continued its barrage of H1N1 flu vaccine news by announcing that its product passed an experts’ evaluation organized by the SFDA. After spending August 30 and 31 looking at data from the vaccine’s recent clinical trial, the experts recommended approval of the product. The data and the evaluation will be submitted to the SFDA, and Sinovac expects to be given a production license later this week. Sinovac's shares soared following the announcement. More details...

Stock Symbol: (NYSE Amex: SVA)

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.